Ruvalcaba-Myhre-Smith Syndrome (ICD-10-CM Code: E71.440)

Name of the Condition

• Ruvalcaba-Myhre-Smith syndrome.

Summary

Ruvalcaba-Myhre-Smith syndrome is a rare genetic disorder characterized by developmental delays, distinctive facial features, and other systemic manifestations. It is part of a group of conditions affecting growth and neurological development, with symptoms typically emerging in early childhood. The syndrome may involve multiple organ systems, requiring comprehensive evaluation and management.

Causes

This syndrome is caused by mutations in the gene responsible for regulating cellular processes, though the exact genetic mechanism remains under study. It is inherited in an autosomal dominant pattern, meaning a single copy of the altered gene from one parent can cause the condition. De novo mutations (new mutations not inherited from parents) may also occur.

Risk Factors

• Family history of Ruvalcaba-Myhre-Smith syndrome.
• Advanced parental age (associated with de novo mutations).
• No known environmental or lifestyle risk factors.

Symptoms

• Developmental delays or intellectual disability.
• Distinctive facial features (e.g., broad forehead, hypertelorism).
• Short stature or growth abnormalities.
• Skeletal anomalies (e.g., limb differences).
• Gastrointestinal or genitourinary issues.
• Neurological symptoms (e.g., seizures, hypotonia).

Diagnosis

Diagnosis is based on clinical evaluation, including physical examination and assessment of developmental milestones. Genetic testing, such as whole-exome sequencing, may confirm the presence of pathogenic variants. Imaging or laboratory tests may be used to evaluate associated organ system involvement.

Treatment Options

Management is supportive and multidisciplinary, addressing specific symptoms and complications. Interventions may include physical therapy, speech therapy, educational support, and monitoring for systemic issues. No cure exists, but early intervention can improve quality of life.

Prognosis and Follow-Up

Prognosis varies depending on the severity of symptoms and associated complications. Regular follow-up with specialists (e.g., neurologists, geneticists) is recommended to monitor development and address emerging issues. Lifelong care may be necessary for some individuals.

Complications

• Severe developmental delays or intellectual disability.
• Recurrent infections or organ system dysfunction.
• Behavioral or psychiatric challenges.
• Reduced life expectancy in severe cases.

Lifestyle & Prevention

No specific lifestyle modifications prevent the syndrome, as it is genetic. Genetic counseling is advised for families with a history of the condition to discuss recurrence risks and reproductive options.

When to Seek Professional Help

Seek medical attention if developmental delays, unusual physical features, or systemic symptoms (e.g., seizures, growth issues) are observed. Early evaluation by a geneticist or pediatrician is critical for timely intervention.

Tips for Medical Coders

Document the presence of characteristic features (e.g., facial dysmorphism, developmental delays) to support code assignment. Ensure clinical correlation with genetic testing results when available. Code E71.440 is specific to Ruvalcaba-Myhre-Smith syndrome and should not be used for other carnitine metabolism disorders.